A signature of immune function genes associated with recurrence-free survival in @entity0 XXXX .

@entity1 @entity0 @entity5 @entity189 @entity982 @entity1722
The clinical significance of @entity5 -infiltrating immune cells has been reported in a variety of @entity1 @entity189 including @entity0 . However, molecular signature of @entity5 -infiltrating immune cells and their prognostic value in @entity0 @entity1 remain elusive. We hypothesized that a distinct network of immune function genes at the @entity5 site can predict a low risk versus high risk of distant relapse in @entity0 @entity1 regardless of the status of ER, PR, or @entity1722 in their @entity5 . We conducted retrospective studies in a diverse cohort of @entity0 @entity1 with a 1-5  year @entity5 relapse versus those with up to 7  years relapse-free survival. The RNAs were extracted from the frozen @entity5 specimens at the time of diagnosis and subjected to microarray analysis and real-time RT-PCR. @entity982 -embedded tissues were also subjected to immunohistochemistry staining. We determined that a network of immune function genes involved in B cell development, interferon signaling associated with allograft rejection and autoimmune reaction, antigen presentation pathway, and cross talk between adaptive and innate immune responses were exclusively upregulated in @entity1 with relapse-free survival. Among the 299 genes, five genes which included B cell response genes were found to predict with >85% accuracy relapse-free survival. Real-time RT-PCR confirmed the 5-gene prognostic signature that was distinct from an FDA-cleared 70-gene signature of MammaPrint panel and from the Oncotype DX recurrence score assay panel. These data suggest that neoadjuvant immunotherapy in @entity1 with high risk of relapse may reduce @entity5 recurrence by inducing the immune function genes.
